The rise of Sildenafil initially sparked a period of growth for the drug industry, nevertheless recent changes present a uncertain outlook for shareholders. Off-patent alternatives are eroding profits, and persistent https://zoyaoxqu405321.slypage.com/41741742/the-blue-pill-and-big-pharma-a-risky-play